Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Shafrin

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Inquiry : a Journal of Medical Care Organization, Provision and Financing|May 27, 2017
Geographic Variation in Diagnostic Ability and Quality of Care Metrics: A Case Study of Ankylosing Spondylitis and Low Back PainJason Shafrin, Jenny Griffith, Jin Joo Shim, et al.
Journal of Medical Economics|November 9, 2020
Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016Joanna P MacEwan, Syvart Dennen, Rebecca Kee, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid ArthritisJason Shafrin, Arijit Ganguli, Yuri Sanchez Gonzalez, et al.
Journal of Medical Economics|November 26, 2025
Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measuresShanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, et al.
Journal of Medical Economics|January 18, 2019
The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patientsAhva Shahabi, Jason Shafrin, Lauren Zhao, et al.
Journal of Medical Economics|July 19, 2018
The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United StatesKatalin Bognar, Jason Shafrin, Michelle Brauer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 15, 2018
Long-Term Health and Economic Value of Improved Mobility among Older Adults in the United StatesMina Kabiri, Michelle Brauer, Jason Shafrin, et al.
Journal of Managed Care & Specialty Pharmacy|March 29, 2021
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reportsJason Shafrin, Syvart Dennen, Priti Pednekar, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 17, 2018
Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illnessJason Shafrin, Katalin Bognar, Katie Everson, et al.
Cancer Reports (Hoboken, N.J.)|May 19, 2025
Meta-Analysis of Recurrence-Free Survival or Disease-Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer TrialsUchechukwu Love Anyaduba, Oluwatosin Qawiyy Orababa, Zion Faye, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Inquiry : a Journal of Medical Care Organization, Provision and Financing|May 27, 2017
Geographic Variation in Diagnostic Ability and Quality of Care Metrics: A Case Study of Ankylosing Spondylitis and Low Back PainJason Shafrin, Jenny Griffith, Jin Joo Shim, et al.
Journal of Medical Economics|November 9, 2020
Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016Joanna P MacEwan, Syvart Dennen, Rebecca Kee, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid ArthritisJason Shafrin, Arijit Ganguli, Yuri Sanchez Gonzalez, et al.
Journal of Medical Economics|November 26, 2025
Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measuresShanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, et al.
Journal of Medical Economics|January 18, 2019
The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patientsAhva Shahabi, Jason Shafrin, Lauren Zhao, et al.
Journal of Medical Economics|July 19, 2018
The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United StatesKatalin Bognar, Jason Shafrin, Michelle Brauer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 15, 2018
Long-Term Health and Economic Value of Improved Mobility among Older Adults in the United StatesMina Kabiri, Michelle Brauer, Jason Shafrin, et al.
Journal of Managed Care & Specialty Pharmacy|March 29, 2021
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reportsJason Shafrin, Syvart Dennen, Priti Pednekar, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 17, 2018
Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illnessJason Shafrin, Katalin Bognar, Katie Everson, et al.
Cancer Reports (Hoboken, N.J.)|May 19, 2025
Meta-Analysis of Recurrence-Free Survival or Disease-Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer TrialsUchechukwu Love Anyaduba, Oluwatosin Qawiyy Orababa, Zion Faye, et al.
Pageof 9